NAB2: A Potential Drug Target and Biomarker for Melanoma (G4665)

Target Name: NAB2

NCBI ID: G4665

NAB2

NAB2: A Potential Drug Target and Biomarker for Melanoma

Melanoma is a type of skin cancer that is often deadly and has a high incidence rate, particularly in geographic regions with high sun exposure, such as Hawaii and California. It is characterized by the rapid growth of skin cells that can eventually form a tumor. Despite advances in treatment, the survival rate for melanoma remains high, with a five-year survival rate of only around 30%.

The discovery of NAB2, a protein that is expressed in high levels in melanoma tissue, has identified a potential drug target and biomarker for this disease. NAB2 is a member of the N-terminal intron family, a family of proteins that are involved in various cellular processes, including cell signaling, DNA replication, and response to environmental stress.

The N-terminal intron family also includes the well-known protein p53, which is a tumor suppressor that plays a central role in preventing the development and progression of cancer. p53 has been implicated in the development of melanoma, as studies have shown that p53 mutations are frequently observed in melanoma tissue.

In addition to its potential role in cancer development, NAB2 has also been shown to play a key role in the regulation of skin pigmentation. It has been shown to interact with the protein called Melanin, which is responsible for the dark color of the skin.

The discovery of NAB2 and its potential as a drug target and biomarker for melanoma has important implications for the development of new treatments for this disease. By targeting NAB2 with drugs, researchers hope to inhibit its function and disrupt its role in the growth and progression of melanoma.

In addition to its potential as a drug target, NAB2 has also been shown to be a potential biomarker for melanoma. The high expression of NAB2 has been observed in melanoma tissue, which could make it an useful indicator for the disease. This could be useful for the development of new diagnostic tests for melanoma, as well as for monitoring the effectiveness of existing treatments.

Overall, the discovery of NAB2 has identified a potential drug target and biomarker for melanoma. Further research is needed to understand its role in the disease and to develop effective treatments. By the end of the year, it is hoped to continue to make significant progress in the fight against melanoma.

Protein Name: NGFI-A Binding Protein 2

Functions: Acts as a transcriptional repressor for zinc finger transcription factors EGR1 and EGR2. Isoform 2 lacks repression ability (By similarity)

The "NAB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets